Literature DB >> 7534104

CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes.

M Hertl1, F Jugert, H F Merk.   

Abstract

There is evidence that T lymphocytes play a critical role in the pathogenesis of drug-induced bullous exanthems. Sulphonamides are known to be among the most frequent aetiological agents in these severe drug-induced cutaneous hypersensitivity reactions. Several studies indicate that cytochrome P450-dependent metabolites of sulphonamides act as the nominal allergens. A 70-year-old woman with a severe blistering exanthem caused by cotrimoxazole (sulphamethoxazole and trimethoprim) was studied. We employed an in vitro approach to determine whether cytochrome P450-dependent enzymes activated drug-specific T lymphocytes from this patient. Immunohistochemical analysis of involved skin revealed a majority of epidermal CD8+ T lymphocytes, whereas the dermal infiltrate was composed of both CD4+ and CD8+ T cells. Dermal T lymphocytes isolated from lesional skin proliferated in response to sulphamethoxazole, but not to trimethoprim, in the presence of autologous mononuclear cells used as antigen-presenting cells. The antigen-specific response of sulphamethoxazole-specific T cells was significantly augmented in the presence of murine liver microsomes with P450-dependent catalytic activities. Our observations suggest that some cutaneous hypersensitivity reactions to sulphamethoxazole are due to drug-specific T lymphocytes. Cytochrome P450-dependent enzymes may play a critical role in the formation of the nominal antigen, which is recognized by antigen-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534104     DOI: 10.1111/j.1365-2133.1995.tb05016.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; C Burkhart; A E Cribb; W J Pichler; B K Park
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  [Pharmacogenetics].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

Review 3.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 5.  T cells in drug allergy.

Authors:  Werner J Pichler
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

Review 6.  [Bullous drug reactions].

Authors:  M S Hertl-Yazdi; M Hertl
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

Review 7.  Gene polymorphisms within the immune system that may underlie drug allergy.

Authors:  Rob J Vandebriel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-03       Impact factor: 3.000

8.  Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01.

Authors:  Jirawat Pratoomwun; Paul Thomson; Kanoot Jaruthamsophon; Rawiporn Tiyasirichokchai; Pimonpan Jinda; Ticha Rerkpattanapipat; Wichittra Tassaneeyakul; Nontaya Nakkam; Pawinee Rerknimitr; Jettanong Klaewsongkram; Yuttana Srinoulprasert; Munir Pirmohamed; Dean J Naisbitt; Chonlaphat Sukasem
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

Review 9.  Immunopharmacology of hypersensitivity reactions to drugs.

Authors:  Dean J Naisbitt; Munir Pirmohamed; B Kevin Park
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

10.  Immunologic evaluation of drug allergy.

Authors:  Enrique Gómez; Maria Jose Torres; Cristobalina Mayorga; Miguel Blanca
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-30       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.